A phase I/II, open-label, nonrandomized, dose-finding safety, tolerance, pharmacokinetic, and efficacy study of orally administered S-1 in combination with cisplatin in patients with advanced gastric cancer

Trial Profile

A phase I/II, open-label, nonrandomized, dose-finding safety, tolerance, pharmacokinetic, and efficacy study of orally administered S-1 in combination with cisplatin in patients with advanced gastric cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 11 Aug 2009 Actual end date (1 May 2006) added as reported by ClinicalTrials.gov
    • 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 11 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top